8-K: Tenaya Therapeutics Announces Promising Early Data for TN-201 Gene Therapy in Hypertrophic Cardiomyopathy Trial

Tenaya Therapeutics reported positive early data from its MyPEAK-1 clinical trial, showing that TN-201 gene therapy was well-tolerated and demonstrated early signs of efficacy in patients with MYBPC3-associated hypertrophic cardiomyopathy.

Summary

• Tenaya Therapeutics announced early data from the first cohort of patients in the MyPEAK-1 clinical trial for TN-201 gene therapy, which targets MYBPC3-associated hypertrophic cardiomyopathy (HCM).
• The trial included three patients in the first dose cohort (3E13 vg/kg), with assessments at Week 52 for Patient 1, Week 40 for Patient 2, and Week 12 for Patient 3.
• TN-201 was generally well-tolerated, with no cardiac toxicities, complement activation issues, or thrombotic microangiopathy events observed.
• All three patients experienced manageable liver enzyme elevations, which were addressed with corticosteroids.
• The gene therapy showed robust transduction into heart muscle cells, with detectable vector DNA and increasing TN-201 mRNA and MyBP-C protein levels over time.
• At Week 8, Patients 1 and 2 showed cardiac transduction levels above those effective in preclinical models and comparable to other clinical-stage gene therapies.
• Patient 1's TN-201 mRNA expression increased by 50% from Week 8 to Week 52, and MyBP-C protein levels increased by 3% during the same period.
• Clinical measures of HCM mostly remained stable or improved, with stable circulating biomarkers and normalized cardiac troponin I in Patient 2.
• The company anticipates additional data readouts from Cohort 1 and the higher dose Cohort 2 in 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with promising early data, good safety profile, and encouraging signs of efficacy. However, it also acknowledges the risks and uncertainties associated with drug development, which tempers the overall sentiment.

Positives

• TN-201 demonstrated a manageable safety profile with no serious cardiac-related adverse events.
• The therapy achieved robust transduction into cardiomyocytes, exceeding preclinical expectations.
• There was evidence of durable and increasing mRNA expression over time.
• Protein levels showed a modest increase from 8 to 52 weeks in Patient 1.
• Some clinical parameters showed stability and improvement, indicating potential efficacy.
• The Data Safety Monitoring Board (DSMB) endorsed dose escalation to 6E13 vg/kg.

Negatives

• All three patients experienced isolated elevations in liver enzymes, though these were managed with corticosteroids.
• One patient experienced a mild enzyme elevation that was classified as a serious adverse event due to the administration of a corticosteroid bolus.
• TN-201 mRNA expression was lower in humans than in preclinical studies, though still comparable to other clinical-stage cardiac gene therapies.
• Clinical endpoints showed mixed results, with some measures not yet available or interpretable.

Risks

• The clinical trial results are preliminary and may change as patient enrollment continues and more data becomes available.
• There is a risk that TN-201 may not demonstrate safety or efficacy in further clinical testing.
• The company faces risks associated with drug development, including regulatory compliance, funding, and competition.
• The company relies on third parties for various aspects of its operations.
• There is a risk of losing key scientific or management personnel.

Future Outlook

Tenaya plans to continue following the first three patients and anticipates additional data readouts from Cohort 1 and the higher dose Cohort 2 in 2025. The company will also continue to enroll patients in the MyPEAK-1 trial.

Management Comments

• Milind Desai, M.D., noted that the initial patients are typical of those seen in their clinic, with HCM impacting their quality of life.
• Whit Tingley, M.D., Ph.D., stated that the emerging safety profile, excellent uptake into cardiomyocytes, and evidence of transgene RNA and protein expression provide important de-risking of the program.
• Faraz Ali, Tenayas Chief Executive Officer, mentioned that the data is in line with expectations and that the high levels of cardiac transduction and early evidence of increasing transgene expression support their confidence in TN-201s potential.

Industry Context

This announcement is significant in the context of gene therapy development for genetic cardiomyopathies, as it provides early evidence of the potential of TN-201 to address the underlying cause of MYBPC3-associated HCM. The results are being compared to other clinical-stage cardiac gene therapies, indicating a competitive landscape in this area.

Comparison to Industry Standards

• The cardiac transduction levels achieved by TN-201 at Week 8 in Patients 1 and 2 were above those that were effective in preclinical knockout mouse models of disease.
• The levels also performed favorably compared to published levels for other clinical-stage AAV gene therapy agents for genetic cardiomyopathies.
• TN-201 mRNA expression levels were similar to those of other clinical-stage cardiac gene therapies, though lower than those observed in preclinical studies.
• The document references a peer program with AAV9 at 6.7E13 vg/kg and 1.1E14 vg/kg, and TN-201 performed similarly at a lower dose of 3E13 vg/kg.
• The document references a study by Greenberg, NEJM 2024, and Thomas, WORLD Symposium February 2024, for comparison of mRNA expression.

Stakeholder Impact

• Shareholders may view the positive early data as a positive sign for the company's future.
• Patients with MYBPC3-associated HCM may see TN-201 as a potential treatment option.
• Employees may be encouraged by the progress of the clinical trial.
• The company's partners and suppliers may be impacted by the continued development of TN-201.

Next Steps

• Tenaya will continue to follow the first three patients with additional data readouts from Cohort 1.
• The company anticipates data readouts from the higher dose Cohort 2 in 2025.
• Enrollment in Cohort 2 is ongoing.
• The company will continue to analyze biopsy data, including baseline biopsies for Patient 3.

Key Dates

Keywords

TN-201, gene therapy, hypertrophic cardiomyopathy, MYBPC3, clinical trial, cardiac, AAV9, MyBP-C, transduction, mRNA, protein expression